Quantcast
Last updated on April 21, 2014 at 1:20 EDT

Latest Anthrax vaccines Stories

2014-04-07 08:32:23

ANNAPOLIS, Md., April 7, 2014 /PRNewswire/ -- PharmAthene, Inc. (NYSE MKT: PIP) announced today that it has received notice from the Department of Health and Human Services (HHS), Biomedical Advanced Research and Development Authority (BARDA), advising the Company of its decision to de-scope the current SparVax(®) anthrax vaccine contract through a partial termination for convenience. BARDA will provide additional guidance to PharmAthene on the contractual changes, following which...

2014-04-01 16:25:27

ANNAPOLIS, Md., April 1, 2014 /PRNewswire/ -- PharmAthene, Inc. (NYSE MKT: PIP) announced today that data from the Company's SparVax(® )next-generation anthrax vaccine program were recently presented at the 8(th) Annual New Technologies, New Vaccines conference. In a presentation entitled, "Factors that Affect Potency and Stability for a Recombinant Protective Antigen Vaccine," Dr. Bradford Powell, Director, Analytical Sciences at PharmAthene, presented results demonstrating the Company's...

2014-03-10 12:25:52

PINE BROOK, N.J., March 10, 2014 /PRNewswire/ -- Elusys Therapeutics, Inc. (Elusys), a biopharmaceutical company developing antibody therapies to treat infectious disease, announced that the United States Patent and Trademark Office (USPTO) has issued a Notice of Allowance for U.S. Application Serial Number 13/076,082, granting a patent which covers methods of preventing or treating anthrax with ETI-204, the company's anti-anthrax antibody, together with antibiotics. The patent also...

2014-02-04 12:28:56

HONOLULU, Feb. 4, 2014 /PRNewswire/ -- The National Institute of Allergy and Infectious Diseases (NIAID), part of the National Institutes of Health (NIH), has awarded Hawaii Biotech, Inc. a grant to continue the development of anthrax anti-toxin drugs. The small molecule inhibitors under development block anthrax lethal toxin. The award has a first-year period of performance, through Q1 2014, valued at $1.1 million. The grant for the full five-year period equals $7.4 million. Under...

2014-01-15 08:27:45

Milestone Achieved under $9.4 Million NIAID Cooperative Grant PRINCETON, N.J., Jan. 15, 2014 /PRNewswire/ -- Soligenix, Inc. (OTCQB: SNGX) (Soligenix or the Company), a clinical stage biopharmaceutical company focused on developing products to treat serious inflammatory diseases where there remains an unmet medical need, as well as developing several biodefense vaccines and therapeutics, announced today significant steps forward in the development of ThermoVax(TM), its proprietary...

2013-12-17 08:30:18

SAN DIEGO, Dec. 17, 2013 /PRNewswire/ -- Pfenex Inc. today announced that Leidos Holdings, Inc. (NYSE: LDOS) (formerly SAIC) has awarded Pfenex a subcontract in support of the development of an anthrax vaccine containing its recombinant protective antigen (rPA) and a novel, immune-enhancing adjuvant. The prime contract was awarded to Leidos by the National Institute of Allergy and Infectious Diseases (NIAID), part of the National Institutes of Health (NIH), to improve the efficacy of...

2013-12-16 08:20:44

ANNAPOLIS, Md., Dec. 16, 2013 /PRNewswire/ -- PharmAthene, Inc. (NYSE MKT: PIP), a biodefense company developing medical countermeasures against biological and chemical threats, announced today it has received notification from the U.S. Food and Drug Administration (FDA) that its SparVax(®) rPA anthrax vaccine program has been placed on clinical hold. The Agency indicated that the Company will receive a letter providing details of the basis for the clinical hold within thirty days. The...

2013-11-11 12:20:25

ANNAPOLIS, Md., Nov. 11, 2013 /PRNewswire/ -- PharmAthene, Inc. (NYSE MKT: PIP), a biodefense company developing medical countermeasures against biological( )and chemical threats, today announced that new data from the Company's next-generation SparVax(®) recombinant protective antigen (rPA) anthrax vaccine program were published in the November issue of the American Society for Microbiology peer-reviewed journal Clinical and Vaccine Immunology. The article entitled, "Increasing the Potency...

2013-11-05 08:36:07

SAN DIEGO, Nov. 5, 2013 /PRNewswire/ -- Pfenex Inc. today announced that it has awarded Paragon Bioservices a contract for the current Good Manufacturing Practice (cGMP) manufacturing of its rPA based anthrax vaccine. Paragon Bioservices will implement the cGMP-ready Pfenex Expression Technology(TM)-based production process that has been developed at Pfenex, through its vaccines division. Funding will be provided by the Department of Health and Human Services (HHS), through the...

2013-11-04 08:26:49

Solutions company to improve the efficacy of public health and bioterror countermeasures by developing, manufacturing, applying and testing a novel adjuvant for West Nile virus and anthrax vaccine candidates. RESTON, Va., Nov. 4, 2013 /PRNewswire/ -- Leidos (NYSE: LDOS), a national security, health and engineering solutions company, announced it has been awarded a prime vaccine adjuvant development contract by the National Institute of Allergy and Infectious Diseases (NIAID), part of...